Germany· DE-A57-2eb6f999eef74c27
Cerebrum Comp. A Cum Auro Comp.
A medicinal product, registered in Germany by Wala Heilmittel Gmbh.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
The record
At a glance
EMA Article 57 (European Union)- Manufacturer
- Wala Heilmittel Gmbh
- Country
- Germany (DE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d95150ed-82a4-4ac5-9072-2d877a2e7350 GET /v1/drugs/d95150ed-82a4-4ac5-9072-2d877a2e7350?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Sublingual Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Aurum Metallicum Trit. D6, Cerebellum Bovis Gl Dil. D7 (Hab, Vs. 41a), Corpora Quadrigemina Bovis Gl Dil. D7 (Hab, Vs. 41a), Hypophysis Bovis Gl Dil. D7 (Hab, Vs. 41a), Iris Bovis Gl Dil. D7 (Hab, Vs. 41b), Myrrha Trit. D3 (Hab, Vs. 6), Medulla Oblongata Bovis Gl Dil. D7 (Hab, Vs. 41a), Nervus Opticus Bovis Gl Dil. D7 (Hab, Vs. 41a), Retina Et Chorioidea Bovis Gl Dil. D7 (Hab, Vs. 41c), Thalamus Bovis Gl Dil. D7 (Hab, Vs. 41a), Olibanum Trit. D3 (Hab, Vs. 6)",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about Cerebrum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.